Tramacet

Quick links to important sections

Tramacet

Selected form

Treatment option: Pain

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tramacet

Property Description
Active Ingredients Acetaminophen and Tramadol Hydrochloride
Form Oral Tablet (Fixed-dose combination)
Pharmacological Class Opioid in combination with non-opioid analgesic
Common Use General pain management (moderate to severe)
Origin Synthetic

What Type of Medicine is Tramacet?

Tramacet is a prescription-only medicine defined as a specialized fixed-dose combination analgesic, typically administered via the oral route as a tablet. This product is classified within the Pharmacological class of opioids in combination with non-opioid analgesics. As a synthetic preparation, its fixed structure ensures a precise interaction between its two components, a feature recognized for maximizing therapeutic efficacy in pain relief.

This specific combination is also marketed under alternative brand names, such as Ultracet or Zaldiar, all containing the same fixed ratio of active substances. This dual-component approach represents a differentiating feature from the majority of single-agent non-opioid pain relievers.

Composition: Acetaminophen and Tramadol Hydrochloride

The composition of Tramacet features two distinct Active ingredients [INN]: Tramadol Hydrochloride and Acetaminophen (Paracetamol). Tramadol Hydrochloride is a centrally acting synthetic opioid analgesic, while Acetaminophen is a non-opioid analgesic.

The strategic pairing of these two agents is designed to create a powerful synergistic effect. This is a functional advantage, meaning the combined pain-relieving effect is superior to what would be achieved if the two components were simply taken separately, offering a potent solution for comprehensive pain management.

General Purpose and Central Action

The general purpose of Tramacet is the potent management of pain that requires a strong, central-acting intervention. It is typically intended for pain that has not been adequately addressed by non-opioid treatments alone, reflecting its status as a high-efficacy analgesic.

This centralized mechanism is key: the Tramadol component works by modulating pain signals in the Central Nervous System (CNS), and the Acetaminophen component supports this action to elevate the pain threshold. This multi-modal approach supports its standing in clinical practice.

Regulatory References

  1. official drug information from the NIH

What side effects are possible with Tramacet?

Possible side effects and safety information

The safety profile of this medicine, containing Tramadol and Acetaminophen, is officially documented by regulatory authorities, with adverse reactions categorized by frequency and the organ systems affected. The official classifications help structure the documented risks, ranging from commonly reported events to rare, clinically serious reactions.

Frequency Classification Representative Adverse Reactions
Very Common (ge 1/10) Nausea, Dizziness, Somnolence (Drowsiness)
Common (ge 1/100 to < 1/10) Constipation, Vomiting, Dry Mouth, Headache, Tremor, Sweating

The most frequently affected organ systems include Nervous System Disorders (e.g., dizziness, headache) and Gastrointestinal Disorders (e.g., nausea, constipation). Psychiatric Disorders such as confusion and anxiety are also listed.

Serious Adverse Reactions and Constraints

Official labeling highlights several serious adverse reactions. These include the potential for Life-Threatening Respiratory Depression, primarily due to the tramadol component, and the risk of Acute Liver Failure (Hepatotoxicity) associated with the acetaminophen component, particularly if the maximum daily dose is exceeded. The product carries the documented risk of Addiction, Abuse, and Misuse, which is inherent to its opioid content, and the potential for Serotonin Syndrome.

Safety statements in regulatory documents note specific considerations for patient populations. The product is officially contraindicated in severe hepatic impairment. For the pediatric population, use is restricted, being contraindicated in children under 12 years of age. Time-related patterns state that the risk of respiratory depression is greatest during the initiation of therapy or following a dose increase.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose is a serious and life-threatening emergency defined by the dual toxicity of the active components. Documented manifestations from the opioid component include profound sedation, miosis (pinpoint pupils), seizures, and life-threatening respiratory depression which can progress to coma. The second critical risk involves the hepatic system, which may lead to Acute Liver Failure (ALF) from the non-opioid component.

Emergency-Response Statements

All suspected overdose cases, or accidental ingestion, require that patients seek immediate medical attention. This action is mandated due to the potential for severe symptoms and the delayed onset of hepatotoxicity. Official regulatory procedures indicate that management involves component-specific antidotes: Naloxone is indicated to reverse opioid-induced respiratory depression, and N-acetylcysteine (NAC) is required to reduce the risk of liver damage.

Population-Specific Overdose Notes

Regulatory warnings state that accidental ingestion by a child can result in a fatal overdose due to the opioid component. Patients who are elderly or have pre-existing pulmonary disease are also documented as being at an increased risk for life-threatening respiratory depression.

Connection to the Overall Overdose Profile

Regulatory documents define the overdose profile by its combined toxicological risks, emphasizing the critical need for immediate medical assistance. This prompt action ensures the rapid administration of component-specific antidotes to counteract potential central nervous system depression, respiratory failure, and delayed hepatic injury.

Therapeutic Uses of Tramacet

What Tramacet Treats: Main Uses and Benefits

Tramacet is commonly used to help with symptomatic relief for pain classified as moderate to severe.

The medication is applied in clinical settings that involve acute or unstable symptom patterns, and is relevant in situations where symptoms may follow an injury or surgical procedure. It may also be part of symptomatic management for conditions presenting with systemic or localized discomfort, such as established osteoarthritis and certain forms of musculoskeletal discomfort. Applied in contexts where additional symptomatic support is needed, it supports general well-being during symptomatic phases by helping to manage symptoms that interfere with daily comfort.

“The symptomatic support is relevant for easing symptoms that create noticeable physiological strain, and may help patients cope more steadily during difficult episodes.”

This approach is relevant when symptoms become temporarily overwhelming, and contributes to easing the overall symptom load during periods of heightened physical symptoms.


Quick Fact: Symptomatic Relief

  • Target Symptoms: Symptoms that create noticeable physiological strain and interfere with daily comfort.
  • Common Scenarios: Used during phases when symptoms become more noticeable, such as post-operative recovery, acute injury pain, or intensification of chronic joint pain.
  • Patient-Focused Benefit: Provides supportive relief when symptoms become temporarily overwhelming.

Eligibility and Restrictions for Use

Eligibility Scope

The use of Tramacet is strictly governed by regulatory criteria established by authorities like the FDA and EMA, defining specific populations that are permitted or prohibited from using the medicine.

Populations for whom use is Contraindicated:

Absolute prohibitions include all children younger than 12 years of age, and patients under 18 years following tonsillectomy or adenoidectomy. The medicine is also forbidden for individuals with known hypersensitivity to tramadol, acetaminophen, or any component, those with severe hepatic impairment, significant respiratory depression, or gastrointestinal obstruction. Concurrent use with, or within 14 days of stopping, Monoamine Oxidase Inhibitors (MAOIs), or acute intoxication by alcohol or CNS depressants is also contraindicated.

Populations for whom use is Not Recommended/Restricted:

Use is not recommended for patients with severe renal insufficiency (creatinine clearance < 10 mL/min) or severe respiratory insufficiency. It is also not recommended during pregnancy (due to the risk of Neonatal Opioid Withdrawal Syndrome) and during lactation. Use in adolescents (12–18 years) with risk factors for respiratory depression should be avoided, and patients with uncontrolled epilepsy or a history of seizures require specific, careful consideration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Tramacet is a fixed-dose combination product containing Tramadol and Acetaminophen, and its interaction profile involves both components. All documented interaction information is based strictly on government regulatory sources.

Interaction Restrictions and Contraindications

Co-administration with Monoamine Oxidase Inhibitors (MAOIs), including Linezolid, is officially contraindicated. Concomitant use with alcohol is also strictly prohibited. The regulatory profile defines these as high-risk pharmacodynamic interactions, which may result in additive central nervous system (CNS) effects or Serotonin Syndrome.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Substance Class Official Interaction Outcome
Metabolic (CYP) Inhibitors of CYP2D6/CYP3A4 May increase the plasma concentration of Tramadol and decrease the active metabolite.
Metabolic (CYP) Inducers of CYP3A4 (e.g., Carbamazepine, St. John’s Wort) May lead to decreased systemic exposure of Tramadol.
Pharmacodynamic Other CNS Depressants (e.g., opioids, benzodiazepines) Risk of additive CNS depression and profound sedation.
Exposure Modification Oral Anticoagulants (e.g., Warfarin) May increase the International Normalized Ratio (INR).

Co-administration with other serotonergic drugs (e.g., SSRIs) may increase the officially documented risk of Serotonin Syndrome.

Mechanism of Action

How Tramacet Works: Mechanism of Action

The drug’s effect involves the coordinated action of its two active components, Tramadol and Acetaminophen, which interact with separate mechanisms in the Central Nervous System (CNS) to modulate the processing of nociceptive signals.


Dual Central Pain Signal Inhibition

This mechanism describes how the Tramadol component acts simultaneously on two distinct pathways. First, its active metabolite (M1) functions as an agonist at the boldsymbolmu-opioid receptor (OPRM1), influencing the release of key pain-signaling molecules in the CNS. Second, the parent compound inhibits the reuptake of Norepinephrine and Serotonin in the spinal cord, which modulates the activity of the body's descending pain inhibitory pathways. This dual action modulates nociceptive signal propagation toward the brain, influencing the drug's overall mechanism of effect.


Modulation of Central Pain Threshold

The Acetaminophen component targets the Prostaglandin H2 Synthase (COX) enzyme's peroxidase site primarily in the CNS. By reducing the synthesis of Prostaglandins, which act as mediators of central hypersensitivity, this mechanism contributes to an increase in the threshold for central signal activation and facilitates the modulation of thermoregulatory processes (antipyresis). This central modulation complements the Tramadol mechanism by influencing overall central signal excitability.


Mechanistic Multi-Modality and Constraints

The combination operates via a multi-modal effect because the two agents interact with non-overlapping systems (opioid/monoamine and central prostaglandin systems). This coordinated effort modulates multiple points in the signaling pathway. However, the mu-opioid receptor activation relies on the metabolic conversion of Tramadol to the M1 metabolite, a process catalyzed by the CYP2D6 enzyme, which is required for the M1's increased affinity at the receptor.

Dosage and Administration Information

Official Administration Guidelines

Tramacet (a fixed-dose combination of tramadol and acetaminophen) is a prescription-only medicine administered via the oral route as a film-coated tablet. Its use is standardized to follow specific, non-flexible dosing and procedural rules.


Standard Dosing and Frequency

The initial dose for adults and adolescents aged 12 years and over is typically two tablets (75 mg tramadol / 650 mg acetaminophen). Subsequent doses of two tablets are taken as needed for pain, provided the dosing interval is not less than six hours. The maximum dose must not exceed 8 tablets per day (300 mg tramadol / 2600 mg acetaminophen).


Procedural Use and Constraints

The tablets should be swallowed whole with sufficient liquid and must not be crushed, broken, chewed, or split. Administration is permitted with or without food. A mandatory constraint on its use is that the product must not be co-administered with any other medicine containing tramadol or acetaminophen to ensure the daily maximum limits of both components are not exceeded.


Duration and Population-Specific Rules

This medication is indicated for short-term use only, specified as five days or less. For patients with severe renal impairment (creatinine clearance < 30 mL/min), the official dosing interval must be extended to prevent the dose from exceeding two tablets every 12 hours. Use in patients with severe hepatic impairment is generally not recommended.

These official instructions define the required parameters for the administration of the medicine, strictly governing the quantity, timing, and duration of its use.

Recent Clinical Evidence

Tramacet: Recent Clinical Evidence


Evidence for use in Short-Term Acute Pain

The evidence base for the use of this medicine in addressing short-term, sudden pain was studied for short-term, sudden pain in research designs such as Randomized Controlled Trials (RCTs) and systematic reviews. The primary types of research used include RCTs and systematic reviews. These research efforts primarily focused on controlled pain models, such as those that follow dental extractions.

In these studies, researchers examined whether the combination was associated with changes in symptoms over defined, short time intervals. The outcomes monitored were patient-reported experiences of physical discomfort, measured using specific pain rating scales. Research highlights changes measured during the study period when the combination was compared directly against a placebo and its individual active components.


Evidence for use in Chronic Musculoskeletal Pain

Research has also explored the role of this fixed-dose combination in conditions characterized by functional limitations and persistent physical discomfort, such as osteoarthritis and certain forms of chronic back or musculoskeletal pain. The research includes Randomized Controlled Trials (RCTs), Systematic Reviews, and meta-analyses.

These studies explored outcomes related to physical discomfort and daily functioning. The primary outcomes studied included patient-reported pain intensity, monitored using established scoring systems, and changes in the ability to perform daily activities. The findings describe patterns observed in the studies regarding changes in the level of discomfort measured during the study period when compared to the baseline condition.

However, evidence quality varies across studies, and comparative evidence against some other pharmacological treatments remains limited. The observation periods in these trials were generally limited to several weeks or a few months, which is considered a short-term window for assessing conditions associated with long-term symptom management. This means that while research describes how symptoms evolved in the observed populations during the study, long-term effects are not fully established.


Long-Term Studies and Follow-up Durability

For both acute and chronic uses, there is limited information regarding long-term outcomes and the durability of the observed findings. Evidence derived from studies observing chronic conditions typically involved intermediate-term follow-up durations, often ranging up to a few months. The short observation windows mean research provides limited insight into long-term outcomes. Research provides insight into short-term changes within that limited timeframe, but data for symptom patterns and activity levels over many years remain insufficient. Therefore, findings describe group patterns but not personal outcomes regarding the maintenance of functional outcomes.


Evidence in Special Patient Populations

Research has examined the product in groups such as older adults and individuals with specific co-occurring health conditions. Findings describe group patterns related to these specific conditions, but data for certain groups, such as children or women who are pregnant, remain insufficient, and the results apply only to the populations studied.


What Research Remains Uncertain or Limited

Follow-up durations were limited for patients with chronic pain. Comparative evidence is also lacking when attempting to fully assess this fixed-dose combination against the spectrum of other pharmacological treatments available for pain. Furthermore, evidence quality varies across studies, as the measurement of outcomes related to daily functioning was often inconsistent. Study results reflect the specific conditions under which they were conducted and do not determine whether an individual will respond similarly.

Key Studies & References

  1. ULTRACET (tramadol hydrochloride and acetaminophen) tablet - DailyMed
  2. Tramadol and Acetaminophen Tablets - MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Tramacet (FAQ)

Q: What is the difference in composition between Tramacet and plain tramadol medication?

Plain tramadol medication contains only the tramadol hydrochloride component. Tramacet is a fixed-dose combination product that contains both tramadol plus the non-opioid pain reliever acetaminophen. The combination is designed to provide a coordinated effect on pain signaling.

Q: What is serotonin syndrome and how is its risk related to taking Tramacet?

Serotonin syndrome is a serious condition that involves too much of the chemical serotonin in the body, potentially leading to symptoms like altered mental status, high neuromuscular activity (such as rigidity or tremors), and rapid heart rate. Official documents note that the risk of this condition is associated with the tramadol component, particularly when it is taken with other medicines that also increase serotonin levels.

Q: Can Tramacet affect liver function over time?

Regulatory documents carry a strong warning about the potential for acute liver failure (hepatotoxicity) primarily related to the acetaminophen component, especially if the maximum daily dose is exceeded. Due to this risk, the medication is officially contraindicated (forbidden) for patients with severe hepatic impairment.

Q: Does Tramacet interact with blood thinning medications (like warfarin)?

Official warnings state that co-administration with coumarin derivatives, such as warfarin, may cause an increase in the International Normalized Ratio (INR). An increased INR is associated with a higher risk of bleeding and severe bruising. Official documentation indicates that patient monitoring is often necessary when these drugs are used together.

Q: What are the common signs of physical dependence on Tramacet?

Physical dependence is described in regulatory information as a physiological state that can develop with continued use, leading to withdrawal symptoms if the medication is stopped suddenly. Symptoms noted may include anxiety, sweating, insomnia, rigors (shaking), pain, nausea, tremors, and diarrhea.

Q: What is the difference between physical dependence and addiction regarding this medication?

Regulatory documents treat physical dependence and addiction as separate concepts. Dependence is a physiological state where the body adapts to the medicine, leading to measurable withdrawal if it is stopped. Addiction, abuse, and misuse are risks inherent to the opioid component, described as behaviors involving compulsive use despite harm.

Q: What information is generally included in the REMS program requirements for opioids like Tramacet?

Tramacet is included under the Opioid Analgesic REMS (Risk Evaluation and Mitigation Strategy) program required by the FDA. The program is designed to ensure that prescribers and patients receive educational materials on the safe use and the serious risks of the medicine, including addiction, abuse, misuse, and respiratory depression.

Q: Is Tramacet ever prescribed to treat pain that is not severe?

The drug is indicated in regulatory documents for the management of pain that is moderate to moderately severe. It is typically intended for pain that has not been adequately addressed by non-opioid treatments alone.

Q: How long does it usually take for Tramacet to start working (onset of action)?

Clinical research reviewed for the regulatory approval indicated that the onset of pain relief occurred in less than one hour after administration. This rapid action is a key feature of the combined ingredients.

Q: How long do the pain-relieving effects of Tramacet typically last?

The recommended dosing interval in the regulatory documents is not less than six hours between doses. This interval suggests the expected duration of the analgesic effect. Clinical research also found that the duration of pain relief was longer than the acetaminophen component administered alone.

Q: Can Tramacet cause low blood sodium levels?

Although not listed as a common side effect, official labeling for the tramadol component describes the potential for low blood sodium levels, known as hyponatremia. This condition has sometimes been associated with issues in the body’s ability to manage water and salt balance.

Q: Are there specific over-the-counter (OTC) pain relievers that should be avoided with Tramacet?

The regulatory documents strictly prohibit taking Tramacet with any other medication that contains either tramadol or acetaminophen. Regulatory constraints specify this prohibition to prevent exceeding the established maximum daily doses of the active ingredients, which is associated with a risk of serious adverse effects.

Q: What are the general characteristics of withdrawal symptoms associated with stopping Tramacet?

When the medication is discontinued, regulatory documents describe withdrawal symptoms that may include both physical and emotional responses. Common symptoms can include anxiety, sweating, insomnia, rigors (shaking), pain, nausea, tremors, and diarrhea.

Q: Does taking Tramacet for only a few days carry a risk of withdrawal?

The medication is indicated for short-term use only (five days or less) for acute pain. The potential for physical dependence, which can lead to withdrawal, is a risk associated with use. The drug is indicated for short-term use to mitigate this risk.

Q: How does a history of substance abuse affect the use of Tramacet?

Regulatory labeling advises against the use of the tramadol component in suicidal or addiction-prone patients. Official labeling states that prescribers are to assess each patient’s risk for abuse and misuse prior to prescribing and to monitor patients regularly throughout treatment.

Q: What does the medication label mean by "taking the lowest effective dose for the shortest time"?

This key phrase, mandated by the FDA for opioid products, means that the dosage regimen should be initiated with the smallest quantity that provides adequate pain relief. It should also be used for the briefest duration possible that is consistent with the patient's treatment goals. This principle is intended to mitigate the risks associated with opioids, such as addiction and respiratory depression.

Q: Is it true that Tramacet can be habit-forming even when used for a short time?

Regulatory documents carry a Boxed Warning that the medicine exposes users to the risks of addiction, abuse, and misuse. These risks are present and can occur even at recommended doses. The drug itself is specifically indicated for short-term use only, reflecting the need to minimize all potential risks associated with the opioid component.

How should Tramacet be stored and disposed of?

Tramacet (tramadol and acetaminophen) is a Schedule IV controlled substance due to the tramadol component, which requires careful storage to prevent misuse or accidental exposure.

Storage Guidelines

Condition Recommendation
Location Store securely in its original container, out of sight and reach of children and pets. A locked cabinet or lockbox is recommended.
Temperature Keep at room temperature, protected from excessive heat and moisture. Do not store in the bathroom.
Safety After each use, immediately return the medication to its secure storage location.

Disposal of Unused Medication

Never keep expired or unneeded Tramacet. The safest and most environmentally responsible disposal method is a drug take-back program or a DEA-authorized collection site, often available at local pharmacies or police stations.

If a take-back option is not immediately available, consult the FDA’s guidelines. These typically recommend mixing the medication (do not crush tablets) with an unappealing substance, such as used coffee grounds or cat litter, placing the mixture in a sealed container, and discarding it in the household trash. Scratch out all personal information on the prescription label before disposal. Do not flush Tramacet down the toilet unless specifically instructed by the accompanying patient information leaflet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tramacet found in:

A-Z Index: